LUNDBECK
Lu AG09222
This research explores the potential Lu AG09222 has to reduce migraine days more effectively than a placebo. Lu AG09222 is a anti-PACAP antibody that will inhibit PACAP.
Eligibility: Individuals who have not found relief with 2-4 other treatments, began having migraines before they turned 50 years old, and are between 18 and 65 years old.
Status: RECRUITING